{
    "clinical_study": {
        "@rank": "46773", 
        "arm_group": [
            {
                "arm_group_label": "Experimental Treatment A", 
                "arm_group_type": "Experimental", 
                "description": "A single dose of 11 mg tofacitinib modified-release (MR) administered in a fasting state."
            }, 
            {
                "arm_group_label": "Experimental Treatment B", 
                "arm_group_type": "Experimental", 
                "description": "A single dose of 22 mg tofacitinib modified-release (MR) administered in a fasting state."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will explore the drug behavior and safety following single doses of tofacitinib\n      modified-release (MR) 11 mg and MR 22 mg in healthy volunteers."
        }, 
        "brief_title": "A Phase 1 Study To Evaluate The Pharmacokinetics (PK), Safety, And Bioavailability Of A Modified-Release (MR) Formulation Of Tofacitinib In Healthy Volunteers", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male subjects and/or healthy female subjects who are of non-childbearing\n             potential.\n\n        Exclusion Criteria:\n\n          -  Evidence or history of clinically significant hematological, renal, endocrine,\n             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or\n             allergic disease;\n\n          -  Clinically significant infections within the past 3 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01731327", 
            "org_study_id": "A3921132"
        }, 
        "intervention": [
            {
                "arm_group_label": "Experimental Treatment A", 
                "description": "A single dose of 11 mg tofacitinib modified-release (MR) administered in a fasting state.", 
                "intervention_name": "tofacitinib modified-release (MR) formulation", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Experimental Treatment B", 
                "description": "A single dose of 22 mg tofacitinib modified-release (MR) administered in a fasting state.", 
                "intervention_name": "tofacitinib modified-release (MR) formulation", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Phase 1", 
            "relative bioavailability", 
            "modified release", 
            "tofacitinib", 
            "CP-690", 
            "550", 
            "pharmacokinetic"
        ], 
        "lastchanged_date": "December 20, 2012", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921132&StudyName=A%20Phase%201%20Study%20To%20Evaluate%20The%20Pharmacokinetics%20%28PK%29%2C%20Safety%2C%20And%20Bioavailability%20Of%20A%20Modified-Release%20%28MR%29%20Formulation%20Of%20T"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Singapore", 
                    "country": "Singapore", 
                    "zip": "188770"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Singapore"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Randomized, Open-Label, 2-Way Crossover Study To Evaluate The Pharmacokinetics (PK), Safety, And Bioavailability Of Tofacitinib Following Single Oral Dose Of MR 11 mg Compared To MR 22 mg In Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Singapore: Health Sciences Authority", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "AUCinf(dn): Area Under the Curve From Time Zero to Infinity, dose-normalized", 
                "safety_issue": "No", 
                "time_frame": "72 hours post dose"
            }, 
            {
                "measure": "Cmax(dn): Maximum Observed Plasma Concentration (Cmax), dose normalized", 
                "safety_issue": "No", 
                "time_frame": "72 hours post dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01731327"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "AUClast(dn): Area Under the Curve From Time Zero to Last Quantifiable Concentration, dose normalized", 
                "safety_issue": "No", 
                "time_frame": "72 hours post dose"
            }, 
            {
                "measure": "AUCinf: Area Under the Curve From Time Zero to Infinity", 
                "safety_issue": "No", 
                "time_frame": "72 hours post dose"
            }, 
            {
                "measure": "Cmax: Maximum Observed Plasma Concentration", 
                "safety_issue": "No", 
                "time_frame": "72 hours post dose"
            }, 
            {
                "measure": "AUClast: Area Under the Curve From Time Zero to Last Quantifiable Concentration", 
                "safety_issue": "No", 
                "time_frame": "72 hours post dose"
            }, 
            {
                "measure": "Tmax: Amount of time drug takes to reach Cmax", 
                "safety_issue": "No", 
                "time_frame": "72 hours post dose"
            }, 
            {
                "measure": "t \u00bd: Terminal elimination half-life", 
                "safety_issue": "No", 
                "time_frame": "72 hours post dose"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}